Bristol-Myers Squibb Announces Clinical Development Program for Combretastatin A4 Prodrug
Technology Licensed From OXiGENE, Inc.
30-Nov-2000 -
Bristol-Myers Squibb
Company (NYSE: BMY), a world leader in oncology, and OXiGENE,
Inc. (Nasdaq: OXGN, SSE: OXGN), a world leader in the field of vascular
targeting, today reported on an Investigational New Drug (IND) submission
for the systemic use of Combretastatin A4 Prodrug (CA4P). ...
Bristol-Myers Squibb
clinical trials
Formation
+5